Choose a language and wait for the translated text.
Shots:
Immutep has reported new data from the investigator-initiated P-II (EFTISARC-NEO) study of eftilagimod alfa (efti) + Keytruda (pembrolizumab) & radiotherapy as neoadjuvant treatment in patients with high-risk, resectable soft tissue sarcoma at CTOS 2026 (Poster P 448); of 40 enrolled pts, 38 underwent surgery & were evaluated for survival
The study showed a 12mos DFS of 81.1% (18mos estimate also 81.1%, immature), a 12mos local recurrence-free survival of 94.1% & a 12mos distant metastasis-free survival of 86.2%, with a median follow-up of 19.1mos; 8 pts had recurrence as of the Apr 30, 2026 cutoff
Pts with post-treatment TIL levels >310 cells/mm² had a 12mos DFS of 95.0% vs 64.9% with lower levels. Immutep is preparing to advance efti into a registration-directed trial in neoadjuvant soft tissue sarcoma, targeting initiation in 2H CY2027
Ref: Globe Newswire | Image: Immutep | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Immutep Reports Disease-Free Survival Data from the P-II (EFTISARC-NEO) Trial of Eftilagimod Alfa for Soft Tissue Sarcoma at CTOS 2026 appeared first on PharmaShots.
Immutep Reports Disease-Free Survival Data from the P-II (EFTISARC-NEO) Trial of Eftilagimod Alfa for Soft Tissue Sarcoma at CTOS 2026 | PharmaVoice